The Tax-Relief-and-Medicaid-Cuts Bill Nears the Finish Line, With Four Big Implications for the Pharma Industry

  Inflection Point It’s not clear to me that anyone has noticed, but the government weighed in last night on the lawsuits from Johnson & Johnson and BMS challenging the

The “smoothing” provision is the most important part of the IRA that no one has heard of (I mean, you all have heard of it, but I don’t consider any

I don’t think there is a whole lot of analysis needed on the Commonwealth Fund’s look at the impact of high health care costs on consumers. A majority of the